PRE

Prenetics GlobalF

Nasdaq / Health Care Equipment & Services

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$26.00

Analysis reference price unavailable

Analysis 2026-04-15 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$17.00

Analysis reference price unavailable

Analysis 2026-04-15 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$11.00

Analysis reference price unavailable

Analysis 2026-04-15 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

Despite very strong company-reported growth, the deterministic prior is neutral-to-negative and the evidence packet started with zero primary notes, zero recent news, and zero catalyst density. After checking primary company sources, the thesis improves from 'unknown' to 'monitorable,' but not enough to justify a high-conviction bullish call.

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-04-30eventFormal cash-bridge validation after portfolio simplificationHigh impact

Prenetics said the ACT Genomics sale, Europa disposal, and Insighta stake sale lifted adjusted liquidity to about $171M with zero debt; formal filing follow-through that cleanly reconciles those proceeds would help support the balance-sheet floor under a still-transitioning business [#PR-2026-02-18]

2026-05-31catalystIM8 durability check after the Dec-2025 ARR spikeHigh impact

Management said IM8 reached $10.0M monthly revenue in December 2025, or about $120M ARR, while targeting roughly 60% gross margin in 2026; the next operating update needs to show that run-rate held after the holiday quarter rather than peaking temporarily [#PR-2026-02-18].

2026-12-31catalystFY2026 growth path remains ambitious and still unprovenHigh impact

In its Q3 2025 release, Prenetics outlined an IM8-led FY2026 revenue path of $180M-$200M and a much higher year-end revenue run-rate; if repeat purchase, international mix, and customer acquisition economics hold, the stock can rerate, but this is still mainly management guidance rather than independently validated traction [#PR-2025-11-10].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology